Digitisation | August 19, 2022
QPharma launches Ti OrderPoint 2
OrderPoint was designed as an advanced DTR solution from its first release in 2016.
OrderPoint was designed as an advanced DTR solution from its first release in 2016.
Phase 1 dose-escalation study to be conducted at clinical sites in the U.S., the UK, Australia, and the Philippines
Genentech will be granted an exclusive license to develop and commercialize the degrader worldwide, and will be fully responsible for the development and commercialization costs.
GlobalData’s ‘Pharmaceutical Intelligence Center’ observes that India is still in the nascent stage of developing these potential therapies as currently only four cell/gene therapy molecules are being developed in the country.
This biopharmaceutical facility is one most significant private sector investment ever in the Middletown region
The integrated services ensure that NextPoint can bring their molecule to the clinic in a timely manner.
The decision is based on the outcome of a prespecified interim analysis of the Phase 3 AMEERA-5 trial
The OAI classification implies that the US FDA may withhold approval of any pending product applications or supplements filed from this facility till the outstanding observations are resolved
Collaboration supports multiple discovery efforts, including vaccines
The Trial, the first of its kind in Israel, recently obtained approval from the Israeli Ministry of Health and is preparing for participant recruitment.
Subscribe To Our Newsletter & Stay Updated
